scholarly journals Academia versus industry: choosing a career in drug discovery

2020 ◽  
Vol 2 (3) ◽  
pp. FDD45
Author(s):  
Sarah J Caswell
Keyword(s):  
Drug Discovery ◽  
Early Career ◽  
The Future ◽  
Future Drug

SJ Caswell is a Senior Protein Scientist at AstraZeneca (Cambridge, UK) as well as a member of the Future Drug Discovery Early Career Panel. Here she speaks to Editor Jennifer Straiton about her choice of pursuing a career in industry rather than academia, gives her advice to students looking to enter the field of drug discovery and discusses what more can be done to promote equality in STEM.

scholarly journals Melanie Leveridge on ELRIG and a career in drug discovery

2020 ◽  
pp. FDD
Author(s):  
Melanie Leveridge
Keyword(s):  
Drug Discovery ◽  
Early Career ◽  
Laboratory Research ◽  
Early Career Researchers ◽  
Research And Innovation ◽  
Future Drug ◽  
European Laboratory ◽  
Senior Director

Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery.

Facing the future: Drug discovery reconsidered

1996 ◽  
Vol 45 (8) ◽  
pp. 365-369
Author(s):  
M. L. Bliven ◽  
I. G. Otterness
Keyword(s):  
Drug Discovery ◽  
The Future ◽  
Future Drug

scholarly journals Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity

Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1015
Author(s):  
Utsa Bhaduri ◽  
Giuseppe Merla
Keyword(s):  
Drug Discovery ◽  
Protein Degradation ◽  
Ubiquitin Ligase ◽  
Genetic Disorders ◽  
E3 Ubiquitin Ligase ◽  
Ubiquitin Ligases ◽  
E3 Ubiquitin Ligases ◽  
Post Translational Modification ◽  
Disease Biology ◽  
The Future

Ubiquitination is a post-translational modification that has pivotal roles in protein degradation and diversified cellular processes, and for more than two decades it has been a subject of interest in the biotech or biopharmaceutical industry. Tripartite motif (TRIM) family proteins are known to have proven E3 ubiquitin ligase activities and are involved in a multitude of cellular and physiological events and pathophysiological conditions ranging from cancers to rare genetic disorders. Although in recent years many kinds of E3 ubiquitin ligases have emerged as the preferred choices of big pharma and biotech startups in the context of protein degradation and disease biology, from a surface overview it appears that TRIM E3 ubiquitin ligases are not very well recognized yet in the realm of drug discovery. This article will review some of the blockbuster scientific discoveries and technological innovations from the world of ubiquitination and E3 ubiquitin ligases that have impacted the biopharma community, from biotech colossuses to startups, and will attempt to evaluate the future of TRIM family proteins in the province of E3 ubiquitin ligase-based drug discovery.

scholarly journals Arrayed CRISPR reveals genetic regulators of tau aggregation, autophagy and mitochondria in Alzheimer’s disease model

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lishu Duan ◽  
Mufeng Hu ◽  
Joseph A. Tamm ◽  
Yelena Y. Grinberg ◽  
Fang Shen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Discovery ◽  
Disease Model ◽  
Mitochondrial Morphology ◽  
Individual Gene ◽  
Human Genes ◽  
Future Drug ◽  
Tau Aggregation

AbstractAlzheimer’s disease (AD) is a common neurodegenerative disease with poor prognosis. New options for drug discovery targets are needed. We developed an imaging based arrayed CRISPR method to interrogate the human genome for modulation of in vitro correlates of AD features, and used this to assess 1525 human genes related to tau aggregation, autophagy and mitochondria. This work revealed (I) a network of tau aggregation modulators including the NF-κB pathway and inflammatory signaling, (II) a correlation between mitochondrial morphology, respiratory function and transcriptomics, (III) machine learning predicted novel roles of genes and pathways in autophagic processes and (IV) individual gene function inferences and interactions among biological processes via multi-feature clustering. These studies provide a platform to interrogate underexplored aspects of AD biology and offer several specific hypotheses for future drug discovery efforts.

Professional values, job satisfaction, career development, and intent to stay

2016 ◽  
Vol 24 (6) ◽  
pp. 675-685 ◽  
Author(s):  
Susan Yarbrough ◽  
Pam Martin ◽  
Danita Alfred ◽  
Charleen McNeill
Keyword(s):  
United States ◽  
Job Satisfaction ◽  
Career Development ◽  
Intent To Stay ◽  
The United States ◽  
Early Career ◽  
Professional Values ◽  
Convenience Sample ◽  
Hospital System ◽  
The Future

Background: Hospitals are experiencing an estimated 16.5% turnover rate of registered nurses costing from $44,380 - $63,400 per nurse—an estimated $4.21 to $6.02 million financial loss annually for hospitals in the United States of America. Attrition of all nurses is costly. Most past research has focused on the new graduate nurse with little focus on the mid-career nurse. Attrition of mid-career nurses is a loss for the profession now and into the future. Research objective: The purpose of the study was to explore relationships of professional values orientation, career development, job satisfaction, and intent to stay in recently hired mid-career and early-career nurses in a large hospital system. Research design: A descriptive correlational study of personal and professional factors on job satisfaction and retention was conducted. Participants and research context: A convenience sample of nurses from a mid-sized hospital in a metropolitan area in the Southwestern United States was recruited via in-house email. Sixty-seven nurses met the eligibility criteria and completed survey documents. Ethical considerations: Institutional Review Board approval was obtained from both the university and hospital system. Findings: Findings indicated a strong correlation between professional values and career development and that both job satisfaction and career development correlated positively with retention. Discussion: Newly hired mid-career nurses scored higher on job satisfaction and planned to remain in their jobs. This is important because their expertise and leadership are necessary to sustain the profession into the future. Conclusion: Nurse managers should be aware that when nurses perceive value conflicts, retention might be adversely affected. The practice environment stimulates nurses to consider whether to remain on the job or look for other opportunities.

Drug Discovery

2018 ◽  
pp. 399-404
Author(s):  
S. Nassir Ghaemi
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
New Approach ◽  
The Past ◽  
Scientific Exploration ◽  
Clinical Indications ◽  
The Future ◽  
Clinical Diagnoses

Newer and better medications are obtained as part of the drug discovery process, which occurs mainly in the pharmaceutical industry. This process is hampered by excessive attention to marketing demands, as opposed to scientific exploration. It also is impaired by the psychiatric profession’s mistaken ideologies, whether psychoanalytic orthodoxy in the past or DSM beliefs of the present. Wrong clinical phenotypes impair finding new pharmacological mechanisms and targeting them well to the write clinical indications. Perhaps as a consequence, no treatments have been developed in the last few decades, since DSM-III, that are more effective than prior agents. Progress for the future in drug discovery will require not just better neurobiological work, but also a new approach to clinical diagnoses in psychiatry.

scholarly journals Support of Early-Career Researchers Supports the Future of ASLO

2019 ◽  
Vol 28 (1) ◽  
pp. 34-34
Author(s):  
Kaitlin J. Farrell ◽  
Alli N. Cramer ◽  
Kelly L. Hondula ◽  
Seth K. Thompson ◽  
Jacob A. Zwart
Keyword(s):  
Early Career ◽  
Early Career Researchers ◽  
The Future

scholarly journals A new platform for drug discovery

2019 ◽  
Vol 1 (2) ◽  
pp. FDD20
Author(s):  
Tuomas PJ Knowles
Keyword(s):  
Drug Discovery ◽  
Protein Analysis ◽  
Harvard University ◽  
Next Generation ◽  
Biotech Company ◽  
University Of Cambridge ◽  
Future Drug ◽  
The University ◽  
Scientific Officer

Professor Tuomas Knowles gained his PhD in biophysics from the University of Cambridge (UK) in 2007 and went on to work at Harvard University (MA, USA) before returning to Cambridge as a lecturer, gaining professorship in 2015. He is the founder and Chief Scientific Officer of Fluidic Analytics (Cambridge, UK), a biotech company developing next-generation protein analysis platforms that operate under native conditions in solution. Here he speaks to Future Drug Discovery Editor Jennifer Straiton about Fluidic Analytics' new platform Fluidity One-W, discussing how it works and what benefit it can bring to the field of drug discovery.

Sign in / Sign up

Export Citation Format

Share Document